European Primary Care Cardiovascular Society
HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.
ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.
ESC 2020 The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of CV death or HF hospitalization by 25% in HFrEF patients with or without diabetes, compared to placebo.
Results from the EMPEROR-Reduced trial showed that the SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.
Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.
This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.
A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.
A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.
Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.
This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.
The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.
ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.
